Cytogenetic and molecular analysis of MLL rearrangements in acute lymphoblastic leukaemia survivors

Mutagenesis

Volumn 24, Issue 2, 2009, Pages 153-160

  Brassesco, María S ^a   Montaldi, Ana P ^a   Gras, Diana E ^a   Camparoto, Marjori L ^a   Martinez Rossi, Nilce M ^a   Scrideli, Carlos A ^b   Tone, Luiz G ^b   Sakamoto Hojo, Elza T ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Laboratório de Pediatria ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; MIXED LINEAGE LEUKEMIA PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVOR; CHILD; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENE TRANSLOCATION; GENOMIC INSTABILITY; HUMAN; MALE; MOLECULAR CLONING; PERIPHERAL LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; BASE SEQUENCE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 11; CYTOGENETIC ANALYSIS; ETOPOSIDE; GENE REARRANGEMENT; HUMANS; MOLECULAR SEQUENCE DATA; MYELOID-LYMPHOID LEUKEMIA PROTEIN; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVORS; TENIPOSIDE; TRANSLOCATION, GENETIC;

EID: 61649084713     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/gen063     Document Type: Article

References (63)

1. Pui, C. H., Cheng, C., Leung, W. et al. (2003) Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N. Engl. J. Med., 379, 640-649.
2. Byrne, J. (1999) Long-term genetic and reproductive effects of ionizing radiation and chemotherapy agents on cancer patients and their offspring. Theratology, 59, 210-215.
3. Lönning, L., Zimmermann, M., Reiter, A., Kaatsch, P., Henze, G., Riehm, H. and Schrappe, M. (2000) Secondary neoplasms subsequent to Berlin-Frankfurt-Münstr therapy of ALL in childhood: significantly lower risk without cranial radiotherapy. Blood, 95, 2770-2775.
4. Aplan, P. D., Chervinsky, D. S., Stanulla, M. and Burhans, W. C. (1996) Site-specific DNA cleavage within the MLL breakpoint cluster region induced by topoisomerase II inhibitors. Blood, 87, 2649-2658.
5. Ziemin-Van Der Poel, S., Mc Cabe, N. R., Gill, H. J. et al. (1991) Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Natl Acad. Sci. U.S.A., 88, 10735-10739.
6. Pais, A., Amare Kadam, P., Raje, G., Sawant, M., Kabre, S., Jain, H., Advani, S. and Banavali, S. (2005) Identification of various MLL gene aberrations that lead to MLL gene mutation in patients with acute lymphoblastic leukemia (ALL) and infants with acute leukemia. Leuk. Res., 29, 517-526.
7. Sai-Peng, S. and Liu, L. F. (2001) Nucleolytic cleavage of the mixed leukemia breakpoint region during apoptosis. J. Biol. Chem., 276, 31590-31595.
8. Schnitter, S., Wormann, B., Hiddermann, W. and Griesinger, F. (1998) Partial tandem duplications of the MLL gene detectable in peripheral blood and bone marrow of nearly all healthy donors. Am. Soc. Hematol., 92, 1728-1734.
9. Echlin-Bell, D. R., Smith, L. L., Li, L. et al. (2003) Polymorphisms in the MLL breakpoint cluster region (BCR). Hum. Genet., 113, 80-91.
10. Uckum, F. M., Herman-Haten, K., Crotty, M. L. et al. (1998) Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. Blood, 92, 810-821.
11. Liu, Y., Hernandez, A. M., Shibata, D. and Cortopassi, G. A. (1994) BCL2 translocation frequency raises with age in humans. Proc. Natl Acad. Sci. U.S.A., 91, 8910-8914.
12. Biernaux, C., Loos, M., Sels, A., Huez, G. and Stryckmans, P. (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood, 86, 3118-3122.
13. Limpens, J., Stad, R., Vos, C., de Vlaam, C., de Jong, D., Van Ommen, G. J., Shuuring, E. and Kluim, P. M. (1995) Lymphoma associated translocation t(14;18) in blood B cells of normal individuals. Blood, 85, 2528-2536.
14. Bäsecke, J., Griesinger, F., Trümper, L. and Brittinger, G. (2002) Leukemia- and lymphoma-associated genetic alterations in healthy individuals. Ann. Hematol., 81, 64-75.
15. Koishi, S., Kubota, M., Sawada, M. et al. (1998) Biomarkers in long survivors of pediatric acute lymphoblastic leukemia patients: late effects of cancer chemotherapy. Mutat. Res., 422, 213-222.
16. Moorhead, P. S., Nowel, P. C., Hellman, W. J., Battips, D. M. and Hungerford, D. A. (1960) Chromosome preparation of leukocytes cultured from human peripheral blood. Exp. Cell Res., 20, 613-616.
17. Betti, C. J., Villalobos, M. J., Diaz, M. O. and Vaughan, T. M. (2001) Apoptotic triggers initiate translocations within the MLL gene involving the nonhomologous end joining repair system. Cancer Res., 61, 4550-4555.
18. Ewing, B. and Green, P. (1998) Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res., 8, 186-194.
19. Ewing, B., Hillier, L., Wendl, M. C. and Green, P. (1998) Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res., 8, 175-185.
20. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W. and Lipman, D. J. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein data14e search programs. Nucleic Acids Res., 25, 3389-3402.
21. Shusterman, S. and Meadows, A. T. (2000) Long term survivors of childhood leukemia. Curr. Opin. Hematol., 7, 217-222.
22. Balis, F. M. (1997) The challenge of developing new therapies for childhood cancers. Oncologist, 2, I-II.
23. Friedman, D. L. and Meadows, A. T. (2002) Late effects of childhood cancer therapy. Pediatr. Clin. North Am., 49, 1083-1106.
24. Lopes, L. F., De Camargo, B. and Bianchi, A. (2000) Os efeitos tardios do tratamento do câncer infantil. Rev. Assoc. Med. Bras., 46, 277-284.
25. Pedersen-Bjergaard, J., Andersen, M. K., Christiensen, D. H. and Nerlov, C. (2002) Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Am. Soc. Hematol., 99, 1909-1912.
26. Pui, C. H. and Relling, M. V. (2000) Topisomerase II inhibitor-related acute myeloid leukemia. Br. J. Hematol., 109, 13-23.
27. Kubota, M., Hoshino, Y., Doi, H., Ueno, H., Nishida, Y., Hirota, H. and Akiyama, Y. (1994) Myelodysplastic syndrome with t(9;11)(p22;q23) after treatment for B-cell acute lymphoblastic leukemia without epipodophyllotoxins. Acta Haematol., 92, 33-35.
28. Philpott, N. J., Elebute, M. O., Powles, R., Treleaven, J. G., Gore, M., Dainton, M. G., Min, T., Swansbury, G. J. and Catovsky, D. (1996) Platinum agents and secondary myeloid leukaemia: two cases treated only with platinum-based drugs. Br. J. Haematol., 93, 884-887.
29. Langer, T., Metzler, M., Reinhardt, D. et al. (2003) Analysis of t(9;11) chromosomal breakpoint sequences in childhood acute leukemia: almost identical MLL breakpoints in therapy-related AML after treatment without etoposides. Genes Chromosomes Cancer, 36, 393-401.
30. Stanulla, M., Wang, J., Chervinsky, D. S., Thandla, S. and Aplan, P. D. (1997) DNA cleavage within the MLL break cluster region is a specific event which occurs as part of higher-order chromatin fragmentation during the initial stages of apoptosis. Mol. Cell. Biol., 17, 4070-4079.
31. Sim, S. and Liu, L. (2002) Nucleolytic cleavage of the mixed lineage leukemia breakpoint cluster region during apoptosis. J. Biol. Chem., 276, 31590-31595.
32. Dolan, M., Mc Glennen, R. C. and Hirsch, B. (2002) MLL amplification in myeloid malignancies: clinical, molecular and cytogenetic findings. Cancer Genet. Cytogenet., 134, 93-101.
33. Poppe, B., Vandesompele, J., Schoch, C. et al. (2003) Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood, 103, 229-235.
34. Slany, R. K. (2005) When epigenetics kills: MLL fusion proteins in leukemia. Hematol. Oncol., 23, 1-9.
35. Karenko, L., Sarna, S., Kahkonen, M. and Ranki, A. (2003) Chromosomal abnormalities in relation to clinical disease in patients with cutaneous T-cell lymphoma: a 5-year follow-up study. Br. J. Dermatol., 148, 55-64.
36. Blanco, J. G., Dervieux, T., Edick, M. J. et al. (2001) Molecular emergence of acute myeloid leukemia during treatment for acute lymphoblastic leukemia. Proc. Natl Acad. Sci. U.S.A., 98, 10338-10343.
37. Baker, A., Cachia, P., Ridge, S., Mcglynn, H., Clarke, R., Whittaker, J., Jacobs, A. and Padua, R. A. (1995) FMS mutations in patients following cytotoxic therapy for lymphoma. Leuk. Res., 19, 309-318.
38. Hattori, M., Tanaka, M., Yamazaki, Y., Nakahara, Y., Tsushita, K. and Utumi, M. (1995) Detection of mayor and minor BCR/ABL fusion gene transcripts in a patient with acute undifferentiated leukemia secondary to treatment with an alkylating agent. Leuk. Res., 19, 389-396.
39. Hiebert, S. W., Sun, W., Davis, J. N. et al. (1996) The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. Mol. Cell. Biol., 16, 1349-1355.
40. Rowley, J. (1999) The role of chromosome translocations in leukemogenesis. Semin. Hematol., 36, 59-72.
41. Loh, M. L., Silverman, L. B., Young, M. L., Neuberg, D., Golub, T. R., Sallan, S. and Gilliland, D. G. (1998) Incidence of TEL/AML1 fusion in relapsed acute lymphoblastic leukemia. Blood, 92, 4792-4797.
42. Roulston, D., Espinosa, R., Nucifora, G., Larson, R., Le Beau, M. and Rowley, J. (1998) CBFA2(AML1) Translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood, 92, 2879-2885.
43. Megonigal, M. D., Cheung, N. V., Rappaport, E. F. et al. (2000) Detection of leukemia-associated MLL-GASP translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc. Natl Acad. Sci. U.S.A., 97, 2814-2819.
44. Seeger, H., Dams, H., Buchwald, D. et al. (1998) TEL/AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. Blood, 91, 1716-1722.
45. Strick, R., Strissel, P., Borgers, S., Smith, S. L. and Rowley, J. D. (2000) Dietary flavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc. Natl Acad. Sci. U.S.A., 97, 4790-4795.
46. Martin, M. E., Milne, T. A., Bloyer, S., Galoian, K., Shen, W., Gibbs, D., Brock, H. B., Slany, R. and Hess, J. L. (2003) Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell, 4, 197-207.
47. Popovic, R. and Zeleznik-Le, N. J. (2005) MLL: how complex does it get? J. Cell. Biochem., 95, 234-242.
48. Felix, C. A., Kim, C. S., Megonigal, M. D. et al. (1997) Panhandle polymerase chain reaction amplifies MLL genomic translocation breakpoint involving unknown partner gene. Blood, 90, 4679-4686.
49. Megonigal, M. D., Rappaport, E. F., Jones, D. H., Kim, C. S., Nowell, P. C., Lange, B. J. and Felix, C. A. (1997) Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc. Natl Sci. Acad. U.S.A., 94, 11583-11588.
50. Hunger, S. P. and Cleary, M. L. (1998) What significance should we attribute to the detection of MLL fusion transcripts? Blood, 92, 709-711.
51. Daser, A. and Rabbitts, T. H. (2005) The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin. Cancer Biol., 15, 175-188.
52. Schoch, C., Schnittger, S., Klaus, M., Kern, W., Hiddemann, W. and Haferlach, T. (2003) AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood, 102, 2395-2402.
53. Xiao, Z., Greaves, M. F., Buffler, P., Smith, M. T., Segal, M. R., Dicks, B. M., Wiencke, J. K. and Wiemels, J. L. (2001) Molecular characterization of genomic AML1-ETO fusions in childhood leukemia. Leukemia, 15, 1906-1913.
54. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 233-255.
55. Kawai, K. and Akasa, H. (1999) Treatment of testicular and second cancer. Gan to Kagaku Ryoho, 26, 2021-2028.
56. Deininger, M. V., Bose, S., Gora-Tybor, J., Yan, X. H., Goldman, J. M. and Melo, J. V. (1998) Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation. Cancer Res, 58, 421-425.
57. Tawn, E. J., Whithose, C. A. and Martin, F. A. (2000) Sequential chromosome aberration analysis following radiotherapy - no evidence for enhanced genomic instability. Mutat. Res., 465, 45-51.
58. M'kacher, R., Girinsky, T., Koscielny, S. et al. (2003) Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients. Int. J. Radiat. Oncol. Biol. Phys., 57, 321-326.
59. Nachman, J., Sather, H. N., Cherlow, J. M., Sensel, M. G., Gaynon, P. S., Lukens, J. N., Wolff, L. and Trigg, M. E. (1998) Response of children with high-risk ALL treated with and without cranial irradiation: a report from the Children's Cancer Group. J. Clin. Oncol., 16, 920-930.
60. Brandalise, S., Odone, V., Pereira, W., Andrea, M. et al. (1993) Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and 85. Leukemia, 7 (Suppl. 2), 142-145.
61. Andersen, M. K., Johansson, B., Larsen, O. S. and Perdersen-Bjergaard, J. (1998) Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica, 83, 483-488.
62. Bäsecke, J., Podleschny, M., Becker, A. et al. (2008) Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma. Br. J. Haematol., 141, 52-59.
63. Brassesco, M. S., Camparoto, M. L., Tone, L. G. and Sakamoto-Hojo, E. T. (2004) Analysis of ETV6/RUNX1 fusions for evaluating the late effects of cancer therapy in all (acute lymphoblastic leukemia) cured patients. Cytogenet. Genome Res., 104, 346-351.